icon8: outcome in progression-free survival for weekly-dose paclitaxel in first-line ovarian cancer
Published 6 years ago • 461 plays • Length 3:27Download video MP4
Download video MP3
Similar videos
-
1:19
relacorilant nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
-
1:10
rebastinib and paclitaxel for advanced/metastatic ovarian cancer
-
5:32
paclitaxel in elderly women with ovarian, primary peritoneal or fallopian tube cancer
-
2:51
bringing change with ttfields therapy in ovarian cancer
-
5:06
asco22 gynecologic oncology: relacorilant combined with nab-paclitaxel in recurrent ovarian cancer
-
2:28
hcrn lun13-175: long term survival of carboplatin, nab-paclitaxel and pembrolizumab in nsclc
-
0:40
utilizing treatment free survival as an endpoint in research
-
1:22
olaparib and paclitaxel for 2nd line gastric cancer therapy
-
0:55
dr. backes on safety profile of lenvatinib and weekly paclitaxel in endometrial cancer
-
1:08
4-year monarche results: increasing benefits with abemaciclib et for er /her2- high-risk early bc
-
4:08
selecting optimal upfront therapy for ovarian cancer
-
1:09
dr. budd discusses paclitaxel regimens in breast cancer
-
5:04
weekly paclitaxel plus bevacizumab for relapsed ovarian sex cord tumors
-
1:07
dr. scribner on the role of chemotherapy in ovarian cancer
-
1:08
immediate implants with guided surgery w/ nikos mattheos | clinical video session 2018
-
4:17
targeting checkpoint inhibitors for cancer treatment: the possibilities
-
4:55
ebmt 2020: cellular therapy day
-
1:49
ip chemotherapy with dfp-10825, ts shrna -liposome - video abstract id 156635